Resurgent BioCryst at It Again
"We believe that positive data anticipated from the proposed phase I trial along with success in its efficacy studies in animals will provide BioCryst with the necessary data for Peramivir to become eligible for government stockpiling," analyst Vinny Jindal of Wedbush Morgan wrote in a recent research report.
According to Jindal, BioCryst has a chance to have one of three major avian flu drugs with Peramivir. The others are Tamiflu, marketed by Gilead (GILD) and Roche, and Relenza, sold by Australia's Biota and GlaxoSmithKline (GSK) of the U.K.
Wedbush Morgan does and seeks to do business with companies covered in its research reports.
Until recently, large pharmaceutical companies lived by a business model focused on marketing prowess and patent protection, according to Brozak. Now, companies like Roche are beginning to focus on understanding technology and acquiring novel developmental drugs.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV